10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

TFCP2L1 Antibody (C-term) Blocking peptide

Synthetic peptide
Catalog # BP13438b

Specification

TFCP2L1 Antibody (C-term) Blocking peptide - Product Information

Primary Accession Q9NZI6

TFCP2L1 Antibody (C-term) Blocking peptide - Additional Information

Gene ID 29842

Other Names
Transcription factor CP2-like protein 1, CP2-related transcriptional repressor 1, CRTR-1, Transcription factor LBP-9, TFCP2L1, CRTR1, LBP9

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP13438b was selected from the C-term region of TFCP2L1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

TFCP2L1 Antibody (C-term) Blocking peptide - Protein Information

Name TFCP2L1

Synonyms CRTR1, LBP9

Function
Transcription factor that facilitates establishment and maintenance of pluripotency in embryonic stem cells (ESCs) (PubMed:25215486, PubMed:26906118). With KLF2, acts as the major effector of self-renewal that mediates induction of pluripotency downstream of LIF/STAT3 and Wnt/beta-catenin signaling (By similarity). Required for normal duct development in the salivary gland and kidney (By similarity). Coordinates the development of the kidney collecting ducts intercalated (IC) and principal (PC) cells, which regulate acid- base and salt-water homeostasis, respectively (By similarity). Regulates the expression of IC genes including subunits B1 and D2 of the V-ATPase complex, OXGR1, CA12, SLC4A1, AQP6 and IC-specific transcription factor FOXI1 (By similarity). Regulates also the

expression of JAG1 and subsequent notch signaling in the collecting duct (By similarity). JAG1 initiates notch signaling in PCs but inhibits notch signaling in ICs (By similarity). Acts as a transcriptional suppressor that may suppress UBP1-mediated transcriptional activation (By similarity). Modulates the placental expression of CYP11A1 (PubMed:10644752).

Cellular Location
Nucleus.

Tissue Location
Highly expressed in placental JEG-3 cells and very low levels of expression in non-steroidogenic cells. No expression was seen in adrenal NCI-H295A cells or in adrenal tissue

TFCP2L1 Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

TFCP2L1 Antibody (C-term) Blocking peptide - Images

TFCP2L1 Antibody (C-term) Blocking peptide - Background

TFCP2L1 is a transcriptional suppressor. May suppress UBP1-mediated transcriptional activation. Modulates the placental expression of CYP11A1.

TFCP2L1 Antibody (C-term) Blocking peptide - References

To, S., et al. PLoS ONE 5 (7), E11702 (2010) :Henderson, Y.C., et al. DNA Cell Biol. 27(2):71-79(2008)Hillier, L.W., et al. Nature 434(7034):724-731(2005)Huang, N., et al. Mol. Endocrinol. 19(2):409-420(2005)Rodda, S., et al. J. Biol. Chem. 276(5):3324-3332(2001)